Iran Press/ Iran News: In an exclusive interview with Iran Press, Biglari noted that vaccines that have reached clinical trial in which at least 30,000 to 40,000 people have been studied, will certainly receive more attention.
"The coronavirus-vaccine companies around the world are being asked to carefully study the evidence and documents that are to be considered for the purchase of the vaccine. By reviewing these documents, it can be judged whether the vaccine is approved and can be used domestically; this is a process that must be carefully monitored by specific controls," he announced.
Biglari noted: "Any vaccine made anywhere in the world, its documentation must be carefully studied and it must be determined whether it is approved or not."
"Fortunately, in Iran, various companies started making the coronavirus vaccine, and there is good technical knowledge in the country to make this vaccine," he added.
He expressed hope that the human tests for the Iranian coronavirus vaccine will be conducted, after passing the animal tests with the very detailed studies that are being carried out.
207/216
Read more:
Novel coronavirus, unprecedented, complicated: official
